A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)

Inclusion Criteria: Base Study: * Patient is male or is a female who either cannot have children or who agrees to use appropriate contraceptive measures * Patient has been on hemodialysis for at least 6 months when informed consent is signed * Patient has received intravenous epoetin alfa or epoetin beta for a least 6 months when the informed consent is signed Extension Study: * Patient completed the base study through Week 12 * Patient tolerated MK2578 and demonstrated compliance with study procedures Exclusion Criteria: * Patient has a life expectancy of less than 6 months * Patient is scheduled for a kidney transplant within the next 6 months * Patient has had a blood transfusion within 12 weeks of screening * Patient has had major surgery within 12 weeks of screening or plans to have surgery * Patient has Human Immunodeficiency Virus (HIV) * Patient has history of blood dyscrasia, hematologic disorders or any other disease known to cause anemia * Patient has severe congestive heart failure (CHF) * Patient has a history of malignant cancer, except certain skin or cervical cancers * Patient has a history of grand mal seizures within the last 6 months